Pharmac seeks views on patient access criteria for COVID-19 treatments – Voxy

Pharmac is releasing the October meeting records of their COVID-19 clinical expert advisory group and seeking feedback on the patient access criteria for two funded COVID-19 treatments – baricitinib and casirivimab and imdevimab (branded as Ronapreve).

“To help us make decisions on which treatments to fund and who should be eligible for them, we set up a COVID-19 clinical expert advisory group,” says Dr David Hughes, Pharmac’s Chief Medical Officer. “They look at the evidence for these treatments, to help us understand how they could benefit New Zealanders.”

“Today, we are releasing the records of their October meeting, where they provided advice on baricitinib, Ronapreve and another treatment, molnupiravir. The records include their recommendations for potential patient access criteria.”

“We use access criteria to ensure the medicines we fund are given to those with the highest health need and those most likely to benefit from the treatment,” says Dr Hughes. “In this consultation we are asking health professionals and stakeholders, including consumer groups, for their feedback on what we are proposing.”

Baricitinib is being proposed for use in hospital for those with moderate to severe symptoms of COVID-19, as an alternative treatment option to tocilizumab if this is not available. Baricitinib is not currently Medsafe approved for use in the treatment of COVID-19 and clinicians will need to comply with section 25 of the Medicines Act 1981.

Ronapreve is being proposed for use in hospital for patients with COVID-19 who have mild to moderate symptoms and are at high risk of progressing to severe disease. We are also proposing that it is given in the community to profoundly immunocompromised people with mild to moderate COVID-19 symptoms.

“We have secured supply of a limited volume of Ronapreve, which we estimate would be sufficient to treat up to a maximum of 12,600 patients with mild to moderate COVID-19 throughout 2022. We expect the first 5,300 courses to be available in New Zealand from January 2022, with additional stock to be delivered from April 2022.”

“There may be others in the community who would benefit from access to Ronapreve, but currently fall outside the currently proposed patient access criteria,” says Dr Hughes. We have sought further advice from the COVID-19 clinical expert advisory group about this, and we will be considering this further in the New Year.”

“Reports show that Ronapreve is successful in treating those with the Delta variant of COVID-19. The evidence is less clear and still emerging for Omicron, but Pharmac is continuing to work as quickly as possible to assess the latest information as it becomes available, and secure access to, further treatments.”

To date, Pharmac has approved funding for tocilizumab and remdesivir, which are both already being used in our hospitals, and we have secured stock of baricitinib. Advance purchase agreements have also been negotiated for Ronapreve, molnupiravir and Pfizer’s antiviral treatment.

“Getting vaccinated is the best defence against COVID-19. For those who do become unwell with COVID-19, I want to reassure New Zealanders that Pharmac is working as quickly as possible to assess, and secure access to, treatments. We are doing this using …….


Leave a Reply

Your email address will not be published. Required fields are marked *



Saffron: A wonder spice – Rising Kashmir

The word “saffron” (Crocus sativus L.)  is derived from the Arabic word za’faran, which translates to “yellow.” Saffron finds its name in the oldest text of Kashmir (Nilamatapurane, Vol-1). Also, in the much celebrated ancient cluster of Kashmir, “Rajtarangini” Kalhana includes Kashmiri saffron among those special attributes which according to the people of Kashmir cannot be available even in the paradise (Nehvi, 2010).Saffron also finds its mention in Kashmiri records which dates back to 5th Century BC (Nauriyal et al., 1977).Iran, India and Spain are the major saffron producing countries of the world. Iran occupies the maximum a…….


[Top 5 Industry News in 2021] Celltrion’s Regkirona wins regulatory nod without a hitch – Korea Biomedical Review

Although the Covid-19 pandemic persisted throughout the year, the healthcare industry continued to fulfill its duty based on experiences of last year. While going all out to develop Covid-19 treatments and vaccines, the industry tried to graft new technologies, including AI, to promote the sector’s development. In the process, the industry revealed problems requiring correction, such as manipulating raw materials and impurities caught in antihypertensive drugs. Still, the sector continued to improve itself in keeping with the changing global healthcare industry amid the Covid-19 crisis. Korea Biomedical Review has compiled the five biggest industry stories in 2021. — Ed.